Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit. Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA ) securities between August 9, 2024 and March 25, 2026 , inclusive (the “Class Period”).

On March 24, 2026, Culper Research published a report alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors,” had confirmed independently that “ starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there .” On this news, ADMA’s stock price fell $3.96, or 29.1%, over two consecutive trading days to close at $9.63 per share on March 25, 2026, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; (3) ADMA lacked adequate internal controls; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired ADMA securities during the Class Period, you may move the Court no later than August 10, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.